Explainable AI Predicts Hematoxicity from Cancer Treatment Using Multimodal Real-World Data
Keyl, J.; Keyl, P.; Lenfers, T.; Hosch, R.; Kiermeyer, N.; Schallenberg, S.; Kim, M.; Bauer, S.; Bechrakis, N.; Forsting, M.; Fuehrer-Sakel, D.; Kebir, S.; Gruenwald, V.; Hadaschik, B.; Haubold, J.; Herrmann, K.; Kasper, S.; Kimmig, R.; Lang, S.; Rassaf, T.; Roesch, A.; Schadendorf, D.; Siveke, J. T.; Stuschke, M.; Sure, U.; Totzeck, M.; Welt, A.; Wiesweg, M.; Egger, J.; Hartmann, S.; Montavon, G.; Nensa, F.; Mueller, K.-R.; Schuler, M.; Kleesiek, J.; Klauschen, F.
Show abstract
Adverse drug effects remain a major barrier to safe and effective cancer therapy, underscoring the need for tools that predict treatment-related toxicities. We analyzed multimodal real-world data from 14,596 cancer patients across 38 cancer entities, encompassing 330 clinical, tumor, and imaging characteristics, along with 89 anticancer agents. Hematological adverse events (HAE), defined by nadirs of hemoglobin, leukocyte, neutrophil, and platelet values within two months of treatment initiation, were highly prevalent (87.7%; 33.1% severe). We developed Toxix, an explainable artificial intelligence (xAI) framework modeling interactions between patient characteristics and drug combinations. Toxix achieved strong predictive performance for severe toxicities (median AUROC 0.85 for anemia; >0.76 for leukopenia, neutropenia, and thrombocytopenia) and was validated in an external cohort of 2,768 patients with non-small cell lung cancer. Model explainability enabled systematic characterization of drug-patient interactions underlying HAEs. Toxix provides a real-world informed framework for personalized and toxicity-aware cancer therapy planning.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Histology-based Prediction of Therapy Response to Neoadjuvant Chemotherapy for Esophageal and Esophagogastric Junction Adenocarcinomas Using Deep Learning 95%
- Towards Predicting 30-Day Readmission among Oncology Patients: Identifying Timely and Actionable Risk Factors 93%
- Simple Linear Cancer Risk Prediction Models with Novel Features Outperform Complex Approaches 93%
Similar papers in this journal
- Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma 94%
- Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition 93%
- Image-Based Consensus Molecular Subtyping in Rectal Cancer Biopsies and Response to Neoadjuvant Chemoradiotherapy 93%
Similar papers in this journal
Similar papers in this journal
- Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence 97%
- Clinical interpretation of integrative molecular profiles to guide precision cancer medicine 96%
- Additivity predicts the efficacy of most approved combination therapies for advanced cancer 94%
Similar papers in this journal
- Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer 94%
- Leveraging Longitudinal Patient-Reported Outcomes Trajectories to Predict Survival in Non-Small-Cell Lung Cancer 94%
- Tumor-specific activity of precision medicines in the NCI-MATCH trial 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.